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2 ABSTRACT 
Bipolar disorder (BD) is a condition with high heritability estimates, suggesting the 
influence of biological determinants. However, identifying the nature of these 
biological determinants has proven to be difficult, even after decades of genetic 
research. Numerous hypotheses exist, and correspondingly, a substantial amount of 
heterogeneous literature claims significant findings. With increasing technological 
advances, larger experiments are being performed both in terms of number of 
subjects included in the studies, as well as measuring genetic elements. This 
includes genome-wide association studies (GWAS), measuring ancient point 
mutations in DNA distributed within a population, also known as Single Nucleotide 
Polymorphisms (SNPs), and statistically testing them for association to a trait of 
interest. The scale of modern biological experiments is truly massive and requires 
appropriate statistical tools, in order to identify statistically significant findings. 
Calculating p-values from empirical data using classical statistical methods is 
relatively straightforward. However, interpreting the findings into a molecular and 
biological context is not straightforward. Publically available data like the genetic 
architecture across populations, knowledge of gene and protein functions may be 
integrated and can aid interpretation of a large number of SNPs, returned from 
GWAS. Grouping genes together into gene sets based on knowledge and statistical 
testing if any gene sets significantly overlap with SNPs and genes associated 
through GWAS is known as gene set analysis, and applications in BD generic 
research is the main focus of this work.  
The first step in gene set analysis is to assign SNPs to genes. This is non-trivial as 
SNPs tend to be located outside the physical boundaries of genes, or located within 
a gene but influences the expression on a neighbouring gene. We show that genetic 
distance (LD) together with physical distance, and not physical distance alone, 
improves SNP to gene assignment, measured by an increase in concordance 
between studies (paper I). SNPs may influence brain function and activity, and there 
is a large interest in identifying characteristic neural patterns in BD. Collecting large 
brain imaging samples are labour intensive and methods for improving statistical 
power are warranted. Gene set analysis improves statistical power by detecting 
recurring associations in related genes. We conduct gene set analysis of moderately 
associated SNPs in a GWAS of an fMRI experiment, and find biological meaningful, 
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but not statistical significant findings (paper II). Genes carry information of how gene 
products shall interact with the cellular environment. We use protein-protein 
interaction data as a contextual filter to test if any genomic regions associated with 
BD contain genes encoding proteins which participate in a common biological 
process, possibly revealing a molecular context in which BD related proteins 
participate. We identify a biological process, genes responsive to oestrogen stimulus, 
as significantly over-represented among BD associated genes (paper III).  
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2.1 NORWEGIAN ABSTRACT 
Bipolar lidelse har høy arvbarhet som antyder genetisk påvirkning. Men selv etter 
flere tiår med genetisk forskning, er de underliggende genetiske faktorene som 
bidrar til å danne sårbarhet for å utvikle bipolar lidelse fremdeles ukjent. Flere 
hypoteser finnes, og en betraktelig og sammensatt vitenskapelig litteratur rapporterer 
om mulige funn. Selv om likheten i DNA mellom mennesker er høy, er det relativt lett 
å finne forskjeller. Spesielt enkeltmutasjoner er vanlige. De fleste enkeltmutasjonene 
mellom mennesker er nedarvet og har et urgammelt opphav og kalles SNPs. Disse 
gamle og nedarvete SNPs bidrar stekt til variasjonen vi kan observere mellom 
mennesker i dag, slik som variasjon i høyde, pigmentering og sårbarhet for å utvikle 
komplekse sykdommer som for eksempel auto immune sykdommer eller psykiske 
lidelser. Teknologiske fremskritt har gjort det mulig å effektivt måle frekvensen av 
disse SNPs i en populasjon, slik at man kan sammenligne frekvensen mellom en 
kontroll populasjon og en syk populasjon. Slik kan man statistisk teste om det er 
noen SNPs og gener som er signifikant assosiert med sykdom, og dermed forstå 
den underliggende biologien bedre. Slike studier kalles “Genome-Wide Association 
Studies” eller GWAS. Å estimere statistisk signifikante assosiasjoner vha. klassiske 
statistiske metoder er relativt enkelt. Men det å tolke funnene er ikke fullt så enkelt. 
Offentlig tilgjengelig data om gen-funksjon, gen-uttrykk og gen-interaksjoner kan 
brukes til å forbedre tolkningen av GWAS resultater. Å gruppere gener sammen, 
basert på kunnskap om gen funksjon, for så å teste om grupper av gener er over-
representert i GWAS resultater kalles gen-sett analyse, og anvendelser innen 
genetisk forskning innen bipolar lidelse er hovedfokuset i denne avhandlingen.  
GWAS returnerer SNPs, og ikke gener. Derfor er det første steget innen gen-sett 
analyse av GWAS resultater å tildele SNPs til gener. Dette er ikke enkelt siden SNPs 
ofte er plassert mellom gener, eller er plassert inni de fysiske grensene til ett gen, 
men påvirker nabogenet. Vi viser at genetisk avstand (LD) sammen med fysisk 
avstand, forbedrer tildelingen av SNPs til gener, målt ved økt konkordans mellom 
studier (artikkel 1). Effekten av SNPs på hjernefunksjon er lite kjent. Årsaken til dette 
er at nåværende teknikker for å måle hjerneaktivitet (fMRI) er omfattende og 
tidkrevende. Dette fører til at det er vanskelig å samle store nok materialer slik at 
man har statistisk styrke til å finne signifikante SNPs som påvirker hjerneaktivitet. Ett 
alternativ er å øke statistisk styrke andre steder i analysen. I denne studien (artikkel 
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II) har vi økt statistisk styrke ved å redusere datamengden av målt hjerneaktivitet til 
nye variabler, og brukt disse nye variablene i GWAS, som vi tolker vha. gen-sett 
analyse. I denne studien klarte vi ikke å finne noen statistisk signifikante funn. Gener 
koder for informasjon om hvordan gen produktet skal interagere med det molekylære 
miljøet. Vi bruker kjente protein interaksjoner som et logisk kontekst filter, for så å 
teste om det er noen gen-sett som er overrepresentert mellom gener assosiert med 
bipolar lidelse. I denne studien finner vi ett signifikant funn, at bipolar assosierte 
gener som interagerer med hverandre er beriket med proteiner som aktiveres av 
estrogen.
Introduction 
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3 INTRODUCTION 
3.1 SEVERE MENTAL DISORDERS 
Severe mental disorders and the state of psychosis can manifest symptoms in 
human behaviour that are bizarre, disturbing and difficult for bystanders and even 
professionals to fully comprehend. Historically, severe mental disorders and 
accompanying psychotic episodes have often been met with superstition and fear, 
sometimes resulting in physical abuse and outright torture, attempting to banish 
possessing daemons. Even in modern times, so-called lunatics were housed in large 
institutional asylums sometimes being subjected to well-intended, but failed 
treatments, like lobotomies and insulin coma therapies. A shift occurred in the 
understanding of mental disorders and bipolar disorder (BD) in the beginning of the 
1950ties by the discovery of mood stabilizing, psychoactive and antipsychotic drugs, 
able to chemically induce and inhibit changes in consciousness, mood, behaviour, 
and perception. Although the treatment and general clinical approach to BD are 
vastly more dignified, many consider the prognosis and current treatment 
unsatisfactory indicated by unexplained heterogeneous outcome and adverse effects 
of current medications. The biological influences in these disorders are not well 
understood and a substantial degree of personal suffering, socioeconomic burden 
and social stigma remains. WHO estimates that all mental disorders combined 
surpass both cancer and cardiovascular disease, when measuring disability-adjusted 
life years of the non-communicable diseases. The present etiological paradigm 
revolves around the classical Diathesis-stress model, where stressful life events 
together with biological predisposition, form vulnerability to these disorders. Although 
several stressful life events including physical, sexual and illegal substance abuse at 
young age are well known risk factors, the largest risk factor is having a first degree 
relative with BD, strongly indicating that BD is a heritable condition. However, the 
biological understanding and well founded knowledge about the underlying genetic 
predisposition of BD at possible dysfunctional biological processes is almost 
completely unknown.  
3.2 A VERY BRIEF HISTORY OF BIPOLAR DISORDER 
The German psychiatrist and one of the founders of modern psychiatry, Emil 
Kraepelin, pioneered the nosological classification of severe mental disorders and 
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psychosis, and in 1893 defined two distinct forms: dementia praecox and manic 
depression, later known as the Kraepelinian dichotomy and schizophrenia and 
bipolar disorder. Subsequent nosological effort further split the manic depressed 
category into unipolar disorder and bipolar disorder, by the Wernicke-Kleist-
Leonhard school (1953), and later a distinction was made in bipolar disorder, 
between depressions with mania and depression with hypomania (1971), later 
known as bipolar type I (BD I) and bipolar disorder type II (BD II), reviewed [1]. The 
nature of the manic state continues to define the two main categories of BD, where 
mania which may include psychotic episodes, while hypomania is considered a 
milder form of mania and the absence of psychosis.  
There are no experimental tests to empirically determine the presence of BD and the 
field of psychiatry remain a descriptive science, where observations of behaviour and 
communication of mental states, feelings and experiences are central in determining 
diagnosis. Misclassification is not uncommon, and it is estimated that a substantial 
percentage of first admissions with psychosis diagnosed as BD, are later re-
diagnosed as schizophrenia (SCZ) and vice versa [2]. Given the heterogeneity of 
symptoms and overlapping symptomology some consider the current nosological 
categorization of mental disorders artificial, old fashioned and obsolete and 
alternative approaches have been proposed, like the floating continuum model, 
where mental disorders could be considered as gradients of pathology and not as 
discrete categories [3-5].  
3.3 DIAGNOSIS AND MEDICATION 
The hallmark clinical symptom of mania or hypomania is pressured speech, a fast 
and loud monologue, where topics revolve around grandiose ideas, often shifting 
topics. Modern diagnosis of mental disorders is currently being defined by the 
influential American Psychiatric Association and the Diagnostic and Statistical 
Manual of Mental Disorders (DSM), fourth edition [6] and the International 
Classification of Diseases, tenth edition, published by the World Health Organization 
(ICD-10) [7]. In DSM-IV, BD is classified under “mood disorders” together with major 
depressive disorder and the milder forms cyclothymic and dysthymic disorders. The 
diagnostic criteria are subject to constant controversy and revisions. DSM-V has 
recently been released (May 2013) and have been criticized by the lack of 
transparency and inventing new disorders, which some consider normal behaviour, 
Introduction 
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like for instance skin picking, binge eating and internet addiction [8], emphasising the 
relativistic nature and cultural context of acceptable behaviour. Further, the current 
leader of the National Institute of Mental Health in the US characterized DSM-V as 
“at best a dictionary”, criticizing its scientific validity [9]. Although controversial, there 
is little doubt that DSM-V remain clinically useful in a wide range of clinical settings 
[10].   
BD I require at least one manic episode or mixed episode. According to DSM-IV, 
mania is defined as a period of abnormal and persistently elevated, expansive or 
irritable mood lasting one week or more. More specifically, the criteria for mania are: 
a) grandiose thoughts or inflated self-esteem b) decreased need for sleep c) 
increased talkativeness d) racing thoughts or flight of ideas e) distractibility f) 
increase in goal-directed activity or psychomotor agitation g) increase in risky 
behaviour. Mixed episodes are the simultaneous occurrence of manic and major 
depressed symptoms for at least one week. BD II is defined as a history of one or 
more episodes of hypomanic and major depressed episodes. The definition of mania 
and hypomania episodes distinguishes BD I and BD II, where hypomania is 
considered a milder form of mania without psychotic features.  
Diagnosis require that the symptoms are not caused by other medical conditions or 
substance abuse, that the severity of symptoms cause social and occupational 
impairment, hospitalization and the exclusion of milder forms, related to BD, like 
cyclothymia or depression [6]. Individuals with BD I may experience psychotic 
episodes, especially in the manic state, while this is rarer in individuals with BD II.  
The pharmacological treatment of the symptoms of BD relies on the serendipitously 
discovered effects of drugs in the late 40ties and early 50ties. Typical classes of 
drugs used to treat extreme moods in BD include lithium, antipsychotics, 
antidepressants, anticonvulsants and benzodiazepines, and administration of these 
drugs depend on the current state of the disorder and the individual response to the 
treatment. Example of typical treatment in BD: treatment for mania with lithium, 
divalproex or atypical antipsychotics. Bipolar depression treated with quetiapine, 
olanzapine or lamotrigine and continuation of effective mood stabilizing drugs to 
maintain normal mood range, and finally psychoeducation to prevent relapse and 
improve treatment adherence [11]. Adverse effects are common and include weight 
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gain, restlessness, extrapyramidal side-effects like tremors and muscle rigidity, 
sedation and sexual dysfunction [12]. The individual responses to these drugs tend 
to be relatively variable, as seen in lithium treatment in BD I where 80% have some 
kind of positive response [13], and 30% responds very well [14].  
3.4 PREVALENCE, OUTCOME AND MORTALITY 
The lifetime prevalence BD I and BD II has been estimated to be 1% and 1.1%, 
respectively [15]. The age of onset has shown to be heritable with three distributions 
with means 16, 26 and 35 [16]. The outcome of BD tends to be somewhat 
ambiguous as “outcome” can be defined as a full recovery and loss of symptoms or 
recovery of social and/or occupational function with the persistence of symptoms. 
DSM-IV defines partial or full recovery as two or less episodes of manic, hypomanic 
or depressed state over 8 weeks [17]. The course of outcome is characterized as 
being heterogeneous, but several factors are associated with functioning where age 
of onset [18], severity of symptoms [19], psychosis [20] and substance abuse [21] 
are all predictors of psychosocial dysfunction. Even with treatment, 37% experience 
relapses of mania or depression within a year [22], and 42% experience relapses 
within two years [17]. The yearly cost of BD in the US was estimated to be 151 billion 
dollars in 2009 [23] (1057 milliarder NOK). The debilitating nature of BD has a large 
impact on adolescent development in terms of education, social function, 
occupational prospects and life expectancy [24, 25]. Individuals with BD have 
reduced life expectancy, caused by both un-natural deaths (suicide, accidents) and 
natural deaths caused by unhealthy lifestyles [26]. The standard mortality rates for 
suicide and natural deaths in individuals diagnosed with BD have been estimated to 
be approximately 20 and 2, respectively [27, 28].  
Although the previous facts may seem somewhat bleak, the heterogeneity in 
psychosocial functioning in individuals with BD should be stressed, where some may 
achieve historical landmarks in human achievement while other may find it difficult to 
accomplish daily tasks . A Swedish register study found high performing pupils in 
public schools had a forth fold increased risk of being later diagnosed with BD [29].   
3.5 ETIOLOGY 
What causes individuals to experience extreme mood swings like mania and major 
depressed episodes in a cyclic pattern, often with psychosis, are almost completely 
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unknown. Known biological, social and psychological factors which increase risk 
have been united in an overall bio-psycho-social paradigm, where several 
hypothesis have been proposed including the popular Kindling hypothesis of mood 
disorders [30], where life stress lower tolerance for mood symptoms in organically 
predisposed individuals. The behavioural approach system dysregulation model [31], 
where functional neural dysconnectivity results in abnormal regulation of motivation, 
reward and goal seeking behaviour and finally the circadian and social rhythm theory 
[32], suggesting a dysfunctional biological clock or life changing events that perturb 
accustomed daily routines.  
The potency of psychoactive or antipsychotic drugs to manifest or alleviate 
symptoms and mood stabilizers to normalize extreme moods in particular mania, 
otherwise characteristic to BD and psychosis, early suggested abnormal 
neurotransmission during episodes and persistence of symptoms in affected 
individuals. A commonly held view was that fluctuating levels of the monoamines 
(noradrenaline, serotonin and dopamine) were responsible for the cyclic nature of 
BD, where high levels caused mania and psychosis and low levels resulted in 
depression. This is also known as the monoamine hypothesis of depression first 
proposed in 1965 [33]. Also dopamine has been suggested to be central in the 
etiology of BD, suggested by the ability to induce or alleviate mania or major 
depressed episodes [34], as well as glutamate [35] and GABA [36]. This rather 
simplified view of a “chemical imbalance” of neurotransmitters of mental disorders 
during the last 50 years, has served as a fruitful model in developing 
pharmacological drugs and understanding neural signalling [37]. Countless studies 
have suggested the involvement of most neurotransmitters in BD [38], an effort 
which is hampered by the inaccessibility of obtaining living human brain tissue and 
obvious ethical considerations. Clear-cut evidence of such a “chemical imbalance” in 
BD or any other mental disorder, is however missing. The clinical effects of the small 
ion, lithium as the main mood stabilizer in bipolar and the association of voltage 
gated calcium CACNA1C suggests channelopathy, similarly as epilepsy, may be 
involved in the pathogenesis of BD [39]. Anti-convulsants, the main medication in 
prevention of epileptic seizures, are commonly used to treat mania as an alternative 
to lithium, further suggesting BD is to some extent a channelopathic disorder [40].   
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There are numerous studies describing characteristic neural features using structural 
and functional brain imaging of BD patients, and the literature is substantial, but 
heterogeneous. Briefly, reductions in several global brain structures have been found, 
including reductions in total brain volume, whole brain matter and frontal lobe volume 
and cortical thinning [41]. A meta-study found similar changes in reduction of whole 
brain volume and frontal lobe volumes. This particular study suggested that age and 
duration of illness are key factors in these alterations, and questions if these 
alterations are diagnosis specific [42]. In addition, there is some controversy in 
determining if alterations in structural features are caused by medications or lifestyle 
of the affected individuals [43-45], analogously to the chicken or egg dilemma. 
Further, the amount of significant findings in brain alterations related to mental 
disorders has been subject to criticism [46], and some argue that neurosciences in 
general tend to be statistically underpowered [47].  
BD runs in families. Although life stressors are known to increase the risk for 
developing BD, such as physical abuse in childhood [48] and illegal substance abuse 
is associated with age of onset [49], a substantial genetic contribution is revealed by 
several twin studies and the heritability of BD has been estimated as high as 90% 
[50-52]. More recently, a population based study in Sweden based on 2 million 
records, having a first degree relative with BD increases relative risk by ~7, and 
adopted children with a biological parent diagnosed with BD have 4 times increased 
relative risk for developing BD. The heritability of BD was in this study estimated to 
be 0.6 (for comparative purposes: celiac disease 0.7 [53], obesity 0.7 [54], BMI = 0.5 
[55], blood pressure = 0.5 [56] and type II diabetes 0.4 [57]). The same study also 
found a considerable overlap with schizophrenia [58]. Although the population based 
heritability estimate is reduced compared to the previous twin studies, the estimate is 
high, and encourages genetic studies such as Genome-Wide Association Studies 
(GWAS).  
3.6 HUMAN GENETIC AND PHENOTYPIC VARIATION 
Modern human phenotypic diversity is the result of layers of past demographic and 
evolutionary events acting over several timescales like population expansion, 
migration, colonization, random genetic drift and evolutionary adaptation to diet, 
infections and climate. Together with inherited genetic history, the current 
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environment shapes contemporary traits in human individuals, like height, 
pigmentation or cognitive abilities. In this context, suffering from a disease or 
disorder can be considered a trait and there is substantial interest in identifying 
underlying genetic factors determining liability to complex diseases and biological 
knowledge which may advance understanding, treatment and potential drug 
discovery in treating complex diseases [59].  
3.6.1  VARIATION IN HUMAN GENETICS 
The inheritance of traits was first described by the well-known monk Georg Johann 
Mendel, experimenting with pea traits, allowing him to deduce patterns of inheritance 
and formulated two breakthroughs in biology: a) traits are paired, but is segregated 
into one copy in gametes, pairing up in the offspring b) traits are inherited 
independently of each other. This model was re-discovered in 1900, and more 
sophisticated models were proposed as the Boveri–Sutton chromosome theory in 
1915 and the ideas of Nikolai Koltsov, hypothesizing a giant hereditary molecule, 
composed of two mirror strands, in 1928 [60]. However, it was not until 1952, that 
DNA was confirmed as the substrate of inheritance, identifying DNA as the genetic 
material of the T2 phage, followed by the discovery of the three- dimensional 
structure of DNA being described one year later by the combined work of Watson, 
Crick, Wilkins and Franklin. Watson and Crick presented in 1957 the central dogma 
in molecular biology, the irreversible directionality in genetics: “DNA makes RNA 
makes protein”, and re-stated it in 1970 [61].  
Variations in human genetics have been known, through microscopy, for several 
decades and include chromosome copy number variation [62], rearrangements [63] 
and fragile sites [64]. Large scale re-arrangements, visible through microscopy by 
chromosome banding, usually result in a genetic condition, a consequence of 
altering the gene dosage of hundreds of genes. However, with increasing genetic 
resolution, more and more genetic variants could be identified [65], where the 
majority of alterations did not seem to have any observable effect [66]. The DNA 
sequence of the human genome was published in a draft sequence in 2001 [67, 68] 
followed by re-vision and completion in 2004 [69], and brought with it several 
fundamental realizations: a) the human genome was composed of approximately 
21,000 genes, far below most estimates b) the majority of the human genome is 
seemingly non-coding and non-functional c) humans are strikingly similar to each 
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other with only ~0.1% differences in DNA sequence. Although humans are highly 
similar to each other, due to recent bottleneck events during speciation, genetic 
differences can easily be detected. Re-sequencing efforts have showed a larger 
genetic difference that previously though, where sister chromatids, within the same 
person, are 99.5% identical [70]. This non-negligible common genetic variation 
between human individuals is thought to influence phenotypic variability including 
susceptibility to complex diseases like cancer, hypertension and mental disorders. 
Genetic differences between humans can be divided into the following categories: 
single nucleotide polymorphisms (SNPs), small insertions and deletions (indels), 
copy number variants (CNV) and structural variations. The Human Genome Project 
[67], the SNP consortium [71] and the International HapMap Consortium [72] have 
collectively identified approximately 10 million common SNPs in a limited amount of 
samples. This figure has been recently adjusted by the 1000 Genomes Project which 
included 1092 genomes from 14 world-wide populations and identified 36.6 million 
SNPs, 1.38 million small indels and 13,800 large deletions. Individuals, on average, 
carry 3.6 million SNPs, 350,000 small indels and ~700 large deletions [73].  
The most abundant category is SNPs, or ancient point mutations. Point mutations 
are substitutions of a single base pair in DNA, compared to another genome. Point 
mutations spontaneously form, due to the near-perfect molecular mechanism of DNA 
replication during cell division and formation of the gametes. The average mutation 
rate pr. DNA base pair is estimated to be ~1.1 × 10−8 pr. site in the haploid genome 
[74]. Having 3,101,804,739 (Ensembl GRCh37.p12, Feb 2009) base pairs in the 
human genome, gives 34 novel mutations per generation (x 2 for sister chromatid). 
The fate of these point mutations are subject to evolutionary forces, and if a point 
mutation is distributed within a population at a frequency above 1%, that mutation is 
denominated a single-nucleotide polymorphism (SNP) [75]. The frequency of any 
given SNP within a population, generally, reflects the age of the point mutation event. 
For example, SNPs shared across all human populations originates before “Out of 
Africa” migration, although they might have very different frequencies between 
populations [76]. The overwhelming majority of SNPs have no functional 
consequences on protein coding DNA sequence, where 0.01% is nonsense SNPs, 
0.02% are frame shift SNPs and 0.8% are missense SNPs (dbSNP 139).  
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Despite the fact that genetic linkage studies were wildly successful in identifying the 
genetic determinants in diseases having a Mendelian pattern of inheritance, also 
known as monogenic diseases, the methodology failed to identify causal genes 
when applied to common diseases and disorders like most cancer types, infertility, 
obesity, auto-immune diseases and mental disorders, conditions which show 
substantial degrees of being heritable. It became apparent, that these diseases were 
not monogenic traits, and the failure to identify clear susceptibility genes, suggested 
a complex inheritance and the need for a different approach altogether [77, 78]. Two 
main hypotheses were proposed in 2001 to explain the nature of genetic 
susceptibility of complex diseases: common disease – common variant model [79] 
and the common disease – rare variant model [80], also known as the CDCV vs. 
CDRV debate [81]. The CDCV model got a head start after the emergence of 
efficient genotyping technologies based on microarrays able to measure the allelic 
state of hundreds-of-thousand SNPs, and the formation of the international HapMap 
consortium [75], a project aimed at producing reference datasets of common SNPs 
in several populations. This resulted in a massive effort striving to identify SNPs 
conferring susceptibility to complex diseases in large case-control studies, including 
the hallmark Welcome Trust Case Control Consortium study [82]. For the first time, 
SNPs possibly involved in forming susceptibility to complex diseases, diseases 
which affect a substantial proportion of a population and are costly for society as a 
whole, could be identified, promising to provide molecular insights of associated 
genes [83]. 
3.6.2  VARIATION IN HUMAN PHENOTYPES AND HERITABILITY  
All humans are phenotypically unique, the net result of a unique genetic inheritance 
and how genes interact with the current environment. Even monozygotic twins obtain 
genetic alterations over time, which may result in phenotypic differences and 
susceptibility to disease [84]. A phenotype is the observational set of one or more 
traits, and as genes tend to control the observational set of traits, phenotypes are 
more or less inherited. The question is to what extent, or the degree of inheritance. 
The influence of genes on a trait is in genetics coined “heritability”. Heritability is 
often misinterpreted as the degree of inheritance or “chance to catch the trait” in an 
offspring or proportion of a trait that is genetic. Heritability is a technical term in 
genetics and is defined as the proportion of phenotypic variation that is due to 
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genetic variation in a specific population [85]. A heritability of 0 equals no genetic 
contribution to phenotypic variation and a heritability of 1 equals all phenotypic 
variation are caused by genetic variation. As simplified examples, the heritability of 
black hair in Asia or being born with ten fingers is 0 (no phenotypic variation) and all 
monogenic disease have a heritability of 1 (no genotypic variation). The heritability of 
a complex trait is not constant and can shift with changes in environment and/or 
genetic constraints imposed by for instance natural or artificial selection [85]. 
Elucidating the genetic basis of complex diseases, the heritability measure can be 
informative, as one can define the trait of interest and measure the genetic variation, 
but not the environment. Thus, heritability estimates can indicate the feasibility of 
genetic studies of complex disease including BD.  
Most human traits are the result of genetic drift, random genetic changes which 
happen to manifest traits, like hitchhikers thumb or dry earwax, while other traits 
have been subject to natural selection like skin pigmentation or lactose tolerance [86, 
87]. In modern genetics the phenotype is not the classical set of observational traits 
like wrinkles on peas or colour in butterfly wings, but used on disease states or 
conditions which may not be observational per se, like hypertension or mental 
disorders. These phenotypes have been considered, by some, as too broad and the 
need for more narrow phenotypes, at a more intermediate level, like blood lipids or 
brain activity has been advocated. Such unobservable or internal phenotypes have 
been coined “endophenotypes” [88].  
3.6.3  ENDOPHENOTYPES 
In genetic epidemiology a good definition of the phenotypic traits of interest, is 
desirable in order to avoid clinical heterogeneity within the trait of interest [89]. There 
has been substantial discussion about the usefulness of psychiatric diagnosis and if 
they serve as good phenotypic traits [88, 90]. The rationale behind this discussion is 
that mental disorders can be considered as somewhat crude and heterogeneous 
categories and behavioural symptoms as high level phenotypes, results of possible 
malfunctioning low level biological processes, such dysfunctional neural activity. By 
identifying measureable and heritable components at a more intermediate level, 
between the disease and genotype levels, would possibly strengthen the ability, by 
larger effect sizes, to detect genetic findings [88, 91, 92]. In the case of the high level 
phenotypes schizophrenia (SCZ) and BD, working memory and response to 
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emotionally charged faces have been, respectively, suggested as possible 
intermediate endophenotypes [93, 94]. As a result, functional MRI (fMRI) 
experiments measuring the neural activation patterns during these tasks can be 
used as endophenotypes, which may reveal possible characteristic neural patterns 
of these disorders [92].  
3.6.4  FUNCTIONAL MRI AS ENDOPHENOTYPES 
The human brain consumes large amounts of energy. During controlled stimulation, 
for instance by solving a cognitive task, activated brain areas have elevated 
neurotransmission, resulting in increased metabolism, demand for oxygen and 
increased blood flow to that area. The Blood-Oxygen-Level Dependant contrast, or 
BOLD response, discovered by Seiji Ogawa in 1990, exploits the magnetic 
properties of haemoglobin, which is paramagnetic when deoxygenized, allowing in 
vivo detection of real-time activation patterns [95], permitting identification of task 
related areas in the brain. Several aspects of brain structure as well as several 
cognitive abilities are seemingly under biological control [92, 96-99]. Combining 
genetic data with the endophenotypes of brain imaging, may allow detection of SNPs 
which influence brain activation patterns, measured by functional MRI [92]. Several 
SNPs and associated genes have been proposed to influence activation patterns 
including the schizophrenia susceptibility genes COMT [100] and ZNF804A [101], 
although these and most other studies do make biased assumptions of regions of 
interest or select a candidate gene of interest. Defining a priori regions of interest or 
candidate genes is generally not recommended since the current understanding of 
gene function on brain regions remains limited. Hypothesis free, whole genome and 
whole brain studies do not make a priori assumptions and promises to deliver a 
global genetic and neurological context, also known as voxel-wide GWAS [102].  
Combining and statistically testing genome-wide data with whole brain images, using 
univariate statistics, results in a large number of statistical tests and the approach 
suffers under a unresolved multiple testing problem [103, 104]. Both data types 
contain a substantial degree of correlated data points and redundancy, and data 
driven techniques which construct new and uncorrelated measurements can be used 
in voxel-wide GWAS, including Principal Component Analysis (PCA) [105] (paper II) 
and Independent Component Analysis (ICA) of fMRI data [106].  
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3.7 GENOME-WIDE ASSOCIATION STUDIES 
It was not until the beginnings of 1990ties that the genetic determinants of medical 
conditions with Mendelian inheritance patterns could be identified using genetic 
linkage, as seen with the identification of cystic fibrous gene in 1989 [107]. Linkage 
studies take advantage of recombination events between sister chromatids [108]. If 
most recombination events in a related family are known, as well as the medical 
status of each individual, inherited chromosomal regions between the affected 
individuals and thus shared genetic regions harbouring a dysfunctional gene, can be 
identified and potentially verified through DNA sequencing [109]. This approach was 
first used on candidate regions, but later whole genome-wide analysis became 
technically possible [110]. Genetic linkage studies rely on measuring genetic 
elements that tend to vary between individuals, thus tracing the pattern of inheritance 
between related individuals. Several types of genetic variation can be measured to 
trace the inheritance of stretches of DNA including point mutations (SNPs) and 
tandem repeats (microsatellites). Microsatellite markers were the most common tool 
to trace the genetic inheritance in linkage studies [111]. Microsatellite markers was 
later replaced by single SNP markers [112], as SNPs are more common and have a 
more dense and uniform distribution on the genome, allowing an increase in 
genomic resolution and capability to detect very short stretches of DNA conferring 
disease susceptibility. Studies measuring SNPs in a population and statistical testing 
them for association to a trait of interest, is known as genome-wide association 
studies (GWAS).  
The GWAS methodology has its origin from traditional gene expression studies, 
where thousands of oligonucleotides, representing genes, are printed on a glass 
slide, taking advantage of the extreme specificity of DNA hybridization [113]. 
Following fragmentation and probe hybridization of a reversed transcribed mRNA 
samples (cDNA), global gene expression can be measured, by luminescence, 
followed by scanning and digitalization. After digitalization, normalization and quality 
control, statistical testing follows, a handful of genes may be found significant, and 
invites biological interpretation [114]. The scale and number of genes to interpret 
gradually increased, as did the difficulty in interpreting the results [115]. Analogously 
to global gene expression studies, GWAS, measuring the qualitative allelic state of 
SNPs in a panel of individuals, are characterized as hypothesis free experiments, 
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overcoming biased prior knowledge and incomplete understanding in disease 
pathophysiology [83]. A landmark GWAS was the Welcome Trust Case-Control 
Consortium (WTCCC) in 2007, reporting findings in seven complex disorders [82]. 
This study sparked numerous follow-up studies and new initiatives aiming to further 
disentangle the genetic susceptibility to complex disorders, including mental 
disorders [116], promising to deliver molecular insights in complex disease pathology 
and the possibility of identifying novel drug targets. Experimentally measuring SNPs, 
also known as genotyping, rely on a large but limited amount of highly informative 
SNPs. 
3.7.1  LINKAGE DISEQUILIBRIUM 
Genetic linkage is a phenomenon in biological inheritance, and linkage disequilibrium 
is a statistical measurement for genetic linkage [117]. Genetic linkage is the 
tendency for neighbouring stretches of DNA to be inherited together, and complete 
linkage is the absence of recombination within a population. The degree of linkage 
can be measured, by linkage disequilibrium (LD), and can be used to intelligently 
select a limited amount of SNPs which capture the majority of genetic variation or to 
infer missing data. For instance, even though 38 million SNPs are known in human 
populations, only a fraction of the most informative SNPs needs to be measured in 
order to conduct genome-wide studies. LD is mainly measured by the squared 
Pearson’s correlation coefficient or r2 between two SNPs, and can range from null to 
one. A pairwise r2 value of 1, between two SNPs, is interpreted as if the two SNPs 
are in complete linkage and the two markers provide the same information, and 
therefore one is redundant. LD is useful when selecting SNPs for genotyping 
platforms, where the most genetically informative SNPs are selected [118]. The 
HapMap consortium has provided reference data for calculating LD in various 
populations [75]. The most informative SNPs are known as tag-SNPs, and by typing 
~500,000 carefully selected SNPs, 80% of total human genetic variation in a 
population are covered [119], and even less for familial linkage studies. 
3.7.2  QUALITY CONTROL 
GWAS are powerful tools, but several issues must be addressed in order to avoid 
spurious findings [114]. Quality control (QC) of the called SNP states is essential, as 
several confounding factors may cause artificial findings. Some of these factors 
include missing data, duplicate samples, fulfilment of Hardy-Weinberg equilibrium, 
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conflict in predicted and annotated gender, cryptic relatedness, inbreeding and 
population stratification [120]. Also the general volatility and sensitivity of the method 
to changes in experimental conditions and equipment should be stressed, and could 
lead to confounding caused by, differing DNA extraction protocols, batches of cases 
only, shipping conditions or choice of technological platform [121]. Even though 
significant findings may be found, additional testing like replication in independent 
samples, fine mapping and re-sequencing are required to identify a causal variant 
[89]. As an example, a GWAS reporting significant SNPs associated with longevity, 
was later found to contain artefacts and unexpected “behaviour” of a subset of SNPs, 
resulting in retraction of the article [122].  
3.7.3  IMPUTATION 
Genome-wide SNP genotyping, measures the allelic state of tag-SNPs, a subset of 
all known SNPs. As the SNP genotyping technology developed, different commercial 
platforms used different strategies for selecting tag-SNPs, complicating replication 
studies and collaborative efforts. The two competing companies Illumina and 
Affymetrix, used different chemistry and strategies in selecting tag-SNPs, which 
resulted in a low direct overlap of selected tag-SNPs [123]. However, tag-SNPs can 
be used to computationally and statistically infer the state of un-genotyped SNPs, 
using the LD structure of a reference population, a method known as SNP imputation 
[124]. SNP imputation is essential in collaborative efforts and mega- and meta-
analyses, combining different genotyping platforms and methods for SNP imputation 
have been developed [125, 126]. SNP imputation results in statistical approximations 
of allele states, also known as SNP dosage. 
3.7.4  STATISTICAL ANALYSIS OF GWAS 
As SNPs are categorical, they can be summarized in contingency tables and several 
statistical tests can be performed using different assumptions, depending on the 
study design and can be divided into two main tests: genotypic or allelic test  [127]. 
The most common test is the allelic 2x2 Pearson’s chi-squared test, which assumes 
an additive effect of alleles. The most common study design in GWAS is the 
observational case-control studies, where the Pearson’s chi-square test or a 
modification of this test called Cochran–Armitage trend test of the minor allele count, 
with one degree of freedom, are used to test for derivations in SNP frequencies 
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between cases and controls. Cohort studies measuring a qualitative trait of interest 
are also common, for instance brain activation (paper II), using logistic or linear 
regression models which allow additional dependant variables like sex or age into 
the model. The mathematics of these models are not elucidated here, see review 
[127].  
A naïve analysis would conclude that significant findings are caused by differences 
in SNP frequencies between the cases and controls populations. However, in 
population genetics other factors may skew allele frequencies, like cryptic 
relatedness, population stratification or inadequate quality control. The non-random 
differences in allele frequencies between populations, caused by the varying 
ancestry of populations and to a lesser extent natural selection, are known as 
population stratification, and is a confounding factor in large, multicentre GWAS 
studies, as demonstrated by the association of SNPs in LCT and height [128]. The 
most common method to adjust for population stratification is to conduct a principal 
component analysis of the SNP data and include several of the retuning 
eigenvectors as independent variables in a logistic regression analysis [129]. This 
relatively simple method has shown to be remarkably efficient, where the genetic 
variants in individuals between populations re-create a near perfect map of modern 
day Europe [130]. Case-control studies, using logistic regression which includes the 
population eigenvalues as independent variables, are the most common approach in 
multicentre case-control studies.  
Since GWAS m statistically tests hundreds-of-thousands of null hypothesis at once, 
correction for multiple testing is in order. The frequentist solution was the 
conservative Bonferroni adjustment method, and a general p-value of p < 5 x 10-8 
was conceived as the golden standard for statistical significance in GWAS [131, 132]. 
Although conservative, this method and most methods for adjusting p-values for 
multiple testing assumes that the tests are independent, this assumption being 
immediately violated by LD between SNPs, leading to over-adjustment and an 
overall increase in type II errors (FN). Although overly conservative, it guaranties the 
absence of type I errors (FP) and it is assumed that clinically important SNPs with 
large effects surpass this threshold. Hundreds of GWAS studies have reported 
numerous significant findings in complex diseases as listed in the NIH GWAS 
catalogue [133].  
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For instance the WTCCC study included both the Cochran–Armitage trend test and 
genotypic test, as well as an empirical Bayesian method [82]. In the case of the first 
PGC SCZ GWAS, logistic regression of imputed SNP dosages using three principal 
components of population structure as covariates, was used in the stage 1 mega-
analysis, and results revolved around speculation of single gene functions and no 
reported systematic efforts, like gene set analysis, was made to interpret the findings 
[134]. With some exceptions, the majority of all GWAS returned astonishingly few 
SNPs with large effects were the mean OR of all significantly associated SNPs is 
1.33 [133].  
3.8 INTERPRETATION OF GWAS 
The first generation of large GWAS reported significant SNPs associated with a trait 
or disease in tables and a Manhattan plot, a genome-wide plot of SNP significance 
across chromosomes, but little effort was spend on systematic analysis of biocurated 
information of associated genes [82], possibly due to the limited amount of SNPs 
passing the stringent threshold of significance. Prior to GWAS, global gene 
expression studies encountered the same challenge of biologically interpreting 
hundreds of significant differentially expressed genes, associated with an 
experimental condition. This was a driving force in the development of 
bioinformatical tools aiming to detect biological similarities within a group of genes, 
based on biomedical knowledge about genes. Biomedical knowledge about genes is 
systematically annotated across numerous databases [135]. The sources of such 
biomedical information may be diverse, ranging from shared biological context as 
indicated by shared Gene Ontology terms [136], recurring words in PubMed 
abstracts or shared functional domains within the protein sequence. Bioinformatical 
tools for performing such analysis are abundant and among the first and most 
successful include DAVID [137], and GSEA [138]. Although highly similar to gene 
expression studies, the GWAS methodology has its own unique issues when 
interpreting results, as they produce a list of SNPs, and not a list of genes.  
Biomedical knowledge about the genome almost entirely revolves around protein 
encoding genes, represented by their physical positions at the start and stop codons. 
As genes occupy approximately 2% of the genome, it is not surprising that the 
majority of SNPs are located outside the physical boundaries of genes [139]. It is 
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common practice that biological interest declines with increasing physical distance 
towards genes. This is simplistic. Take lactase persistence, the autosomal dominant 
trait to digest lactose, as an example. Here, SNPs within two enhancers, determine 
the expression of the LCT gene in adolescence and adulthood. The enhancers are 
located 14 kbps and 22 kbps upstream of the LCT gene and is physically located 
within introns of the neighbouring MCM6 gene [140]. A naive and hypothetical 
GWAS of lactase persistence would find the SNPs within MCM6 highly significant, 
however the role of MCM6 (a DNA helicase) in lactase persistence, would be 
somewhat puzzling. This is a simple example of one of the most important 
challenges when interpreting GWAS results: assigning SNPs to genes.  
3.8.1  ASSIGNING SNPS TO GENES 
In conventional GWAS, each SNP is tested for association to a phenotype of interest 
also known as the single-marker approach [114], and results are presented as a 
ranked list of significant SNPs, where further analysis and interpretation are based 
upon biomedical knowledge of nearby genes [141]. The most simple and common 
method to annotate SNPs to genes, is based by physical distance, where a SNP of 
interest is assigned to the closest gene or genes within a specified distance to the 
SNP. Specifying such a distance is somewhat arbitrary but ten, twenty, fifty or 
hundred kilo-base pairs (kbps) up- or downstream of the SNP is often used. Studies 
combining SNPs with gene expression, aiming to detect cis-regulatory SNPs which 
affect gene expression, also called eQTL studies, have found that the majority of 
SNPs affecting gene expression tend to be located within 20 kbps of the gene it 
exerts its influence [142] (less than 5% are located more than 20kb away from gene).  
However, long range enhances are well known to be involved in monogenic 
conditions where for example regulatory elements 125 kbps downstream of the 
PAX6 gene cause aniridia, X-linked deafness type 3 and deletion of non-coding 
sequence ~1000 kbps upstream of POU3F4, and lastly polydactyly and the long 
range ~1000 kbps upstream enhances of the gene SHH [143].  In the case of lactase 
persistence the two influential enhancers are located 14 and 22 kbps upstream and 
within the MCM6 genes. For instance, a SNP located within a gene and 20 kbps 
upstream of another gene, the first annotation may be kept for further analysis, and 
the second ignored. In the above example, SNPs within the lactase (LCT) enhances, 
would then be annotated to the MCM6 gene, missing LCT altogether. However, the 
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enhancers influencing LCT expression are within 20 kbps and are also in high 
linkage-disequilibrium with SNPs within the LCT gene. Taking advantage of both 
distance and LD between SNPs to aid SNP-gene annotation, have increasingly been 
applied in assigning SNPs to genes including the developed methods and software 
“LDspline” (not available) and “ProxyGeneLD” (Perl script) [144, 145], with the added 
benefit of inferring un-genotyped SNPs to genotyped SNPs using a HapMap 
population reference panel. This also includes “LDsnpR” in paper I.   
Physical position is most often used in assigning SNP to genes, and the significance 
of individual genes most often involves taking the minimum p-value of SNPs within 
the gene to summarize the gene overall significance to the trait of interest. As a 
consequence gene length is an important factor to consider, as larger genes contain 
more SNPs and, by chance, are more likely to contain significant SNPs. The median 
gene length is 20kbps with a standard deviation of 121 kbps, reflecting a high degree 
of variability of the genomic architecture of genes. This is a particular problem in 
neurological genetic studies as genes involved in the nervous system tend to be 
longer, thus neurological genetic studies are prone to find neurological related genes 
by chance [146, 147]. In addition, differences in LD structure and gene clustering on 
the genome have been also shown to be confounding factors [147]. Other methods 
for aggregating SNPs to single gene statistics can be to Bonferroni adjust the 
minimum p-value within the gene or the SNP ratio test, using the second best p-
value or to compare the ratio of significant SNPs (typically p<0.05) versus all SNPs 
within the gene [148]. The variation in gene length, non-random localization of genes 
on the genome is important to keep in mind when assigning SNP to genes, 
especially since paralogous genes, gene duplications and subsequent functional 
divergence, tend to be physical neighbours, but is non-trivial to adjust for these 
confounding factors [144], see figure 1.  
3.8.2  GENES TO GENE SETS 
Gene sets are usually pre-defined and can be derived from high-throughput 
experiments, computationally predicted or manually annotated using literature, and 
can be of varying quality. One of the first initiatives in systematic biocuration was the 
Gene Ontology (GO) consortium, an effort to annotate biological meaning to genes 
using a controlled vocabulary [136], and is still commonly used in gene set 
enrichment studies. GO terms are organized into three different knowledge domains 
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about genes: biological process, molecular function and cellular component, where 
the terms within the three domains are organized in a hierarchical structure starting 
with genetic terms and, going down the hierarchy, increasing the terms specificity. 
Genes are usually annotated with one or more terms from the aforementioned 
domains. These GO terms can be used to test if a group of genes share any terms, 
possibly reflecting a shared biological context of the genes of interest. This approach 
is common and during the last decade, and has routinely been used to interpret 
results from high throughput experiments. Other sources include metabolic pathways 
KEGG and Panther [149, 150], as well as sequence features Pfam [151], protein-
protein interacting networks [152] or text mining in PubMed abstracts [153]. 
3.8.3  STATISTICAL GENE SET ANALYSIS 
Several methods to test the statistical enrichment of biocurated information within a 
gene list have been developed. The methods have their origin in analysis of gene 
expression studies, and can be divided into two main categories: self-contained 
(association) or competitive (enrichment) tests, where the first test “no gene sets are 
associated with the phenotype” and the latter tests “none gene sets genes are no 
more associated with the trait than the non-gene set genes”. Although these two 
hypotheses seems very similar, a distinction is often made [141, 154], although the 
competitive test are wildly more popular. Typical testing of the competitive 
hypothesis includes contingency tables with a following hypergeometric test or the 
GSEA algorithm, see figure 1.  
The most common scenario is to have a list of significant genes from a GWAS, and 
testing the competitive null hypothesis that no gene sets contain more significant 
genes then non-gene set genes. The most frequently used method is to construct 
2x2 contingency table for each gene set, and calculate a p-value based on a discrete, 
univariate probability distribution, most often the hypergeometric distribution [155]. 
Also the Fisher’s exact test and the binomial z-tests are used, and these methods 
differ little in the assumptions being made and produce similar results. However, the 
2x2 contingency tables approach also called over-representation analysis, has been 
criticized for being dependant on the initial threshold of statistical significance, being 
sensitive to the reference gene background and for not taking into account 
interdependency between gene sets [156, 157]. Ranked based methods leverages 
the degree of significance of all genes and a modified version of the Kolmogorov-
   Introduction
29 
 
Smirnov test, called the GSEA algorithm, has been wildly successful in gene set 
analysis of gene expression studies [138]. However, the GSEA algorithm requires a 
summarized value like fold expression or significance for all genes, and may be non-
trivial to ascertain for GWAS results. This method has been criticized to be too 
biased towards the best scoring genes. Both over-representation analysis and the 
GSEA methods are well established, but there is no gold standard for gene set 
analysis and numerous tools have been developed [158, 159]. In this thesis we 
make use of over-representation analysis (paper II and III).   
The first gene set analysis of a GWAS was a study using the GSEA algorithm of 
GWAS of Parkinson’s disease, reporting two significant gene sets [160]. One year 
later a gene set analysis of all seven WTCCC phenotypes using the hypergeometric 
test of contingency tables was used, suggesting multiple biological plausible findings, 
albeit ambiguous statistical significance [161]. 
There are some considerations with gene set enrichment methods caused by 
confounding factors, see figure 1, and these considerations are best handled by 
sample permutation based methods [162]. Permutation based methods (producing 
null results by sample randomization) is, by many, considered the golden standard, 
as it accounts for confounding factors like linkage disequilibrium, gene length and 
SNP coverage present in a GWAS. Algorithms for sample permutations include 
GSEA-SNP [163], GSA-SNP [164], GENGEN [160] and SNP-ratio test [148]. 
However, sample permutation requires the availability of raw genotypes, and as 
most GWAS are large multicentre mega- or meta-studies, the raw genotypes can be 
difficult of obtain and are not publically available, a consequence of the controversy 
in the identifiability of genomic data [165]. Also, there is a considerable 
computational cost. For instance performing 100,000 permutations of a large GWAS 
by using standard GWAS software, PLINK, and would take years to complete [162]. 
Methods which does not require raw genotypes and uses a SNP list with p-values 
include ALLIGATOR [166], MAGENTA [147] and i-GSEA4GWAS [167], although 
these methods are prone to the aforementioned confounding factors. One approach, 
which does not require sample randomization, is to create aggregate gene scores, 
which aims at taking into account the variable degree of number of SNPs within a 
gene [147]. In this thesis, sample permutation test (paper II) and Fisher’s exact test 
(paper III) is used to assess the significance of gene sets.  
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Figure 1: Essential steps for assessing the significance of gene sets from SNPs 
associated with a trait or disease. Adopted from [159].  
3.8.4  GENETIC FINDINGS IN GWAS OF BIPOLAR DISORDER (2010) 
Several genomic regions have been implicated using linkage studies [168], but 
without converging findings. The development of effective SNP genotyping methods, 
GWAS studies allow for far larger samples, able to statistically detect the weak effect 
sizes of single SNPs. The WTCCC study presented the first comprehensive GWAS 
of BD, which included 1868 cases and 2938 controls, reporting four significant 
findings (p<5 x 10-7), where the closest genes were KCNC2, GABRBI, GRM7 and 
SYN3 all related to membrane transport of neurotransmitters and synaptic function 
[168]. Subsequent GWAS of BD included (cases = 1461 and 2008 controls), found 
no significant findings [169] while another study reported one significant finding, 
ANK3 (cases 1098 and 1262 controls) [39]. Further increasing samples in the 
studies (cases=2076 and 1676 controls), reported no significant findings, where the 
most associated region was 1.8 × 10−7 and ITIH1 [170]. As the GWAS field 
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developed including imputation methods increasing the number of SNP tested, a 
stricter statistical significance was as conceived as a new gold standard (nominal p 
value < 5 x 10-8), with further requirement of replication of findings in independent 
samples [171]. The difficulty in replicating findings and missing statistical significance, 
lead to the formation of the Psychiatric GWAS Consortium aiming to unite efforts in 
GWAS in psychiatric genetics [116]. Although the aforementioned studies reported 
significant findings, no clear cut susceptibility genes with large effects was found.  
3.8.5 GENE SET ANALYSIS IN BIPOLAR DISORDER (2010) 
Several studies have reported findings using gene set analysis of GWAS and SNPs 
associated with BD. Here four gene set enrichment studies of the WTCCC BD 
GWAS is summarized: In one of the studies the authors developed their own 
algorithm (ALLIGATOR) [166] and tested for enrichment of GO terms in SNPs 
associated with BD in a meta-analysis [39]. In the study they used different p-value 
cut-offs and identified several broad categories including “autophagy”, “hormone 
activity” and “RNA splicing”. Another study “found heparan sulfate and heparin 
metabolism”, “cytoskeleton remodelling”, “niacin-HDL metabolism” and “glutamate 
regulation of dopamine D1A receptor signalling” significant, using the top 2.5% 
associated genes and assessed significance by comparing the bottom 2.5% to the 
top 2.5% genes using an ad hoc scoring scheme [161]. A third study of the WTCCC 
BD GWAS reported “inositol metabolism”, “chondroitin sulphate biosynthesis” and 
“MAPK signalling pathway” as significant over-represented gene sets [172], while a 
fourth found “ion channel activity-related” terms significantly over-represented in the 
WTCCC BD GWAS [173]. These studies are difficult to compare because they all 
use of different methods including assigning SNP to genes, summing p-values pr. 
gene, different sources for gene sets and different algorithms and tool for performing 
the actual gene set analysis, indicating a need for a gold standard [141]. Also the 
aforementioned studies are limited in that the WTCCC GWAS of BD, which the gene 
sets analysis are based, is somewhat underpowered to identify the very small effects 
of SNPs, limiting the possibility to detect recurring signals between related genes 
[174]. 
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4 AIMS OF THE THESIS 
The overall aim was to gain a better understanding of the molecular mechanisms 
involved in the disease pathology of bipolar disorder (BD) by integrating biomedical 
information about genes, known as gene set analysis, to aid interpretation of on-
going genome-wide association studies (GWAS).  
The first specific aim was to improve methods for assigning SNPs to genes by using 
physical position together with inheritance patterns (linkage-disequilibrium), as 
downstream analysis of GWAS like gene set analysis, require careful SNP to gene 
assignment.  
The second specific aim was to improve statistical power and conduct a GWAS of a 
functional MRI experiment. Statistical power is increased on two levels: 1) by 
principal component analysis of fMRI data and use the reduced data as 
endophenotypes in GWAS and 2) preform gene set analysis of moderately 
associated SNPs.  
The third specific aim was to perform a gene set analysis of a GWAS of BD using 
protein-protein interaction data as a contextual filter. Here we use the results from a 
re-analysis using empirical Bayesian statistics of emerging GWAS results of BD.  
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5 MATERIALS AND METHODS 
The three papers included here are based on different materials, but all include the 
genetic material from the TOP sample. In Paper I we used summary statistics from 
three GWAS of bipolar disorder (BD), including the BD case-control dataset of the 
TOP study. In paper II we used SNP data and functional MRI brain imaging data 
from the TOP study. In the final paper III we used summary statistics from a re-
analysis from the most recent PGC BD GWAS, which include the BD and control 
samples from TOP.  
Table 1 Summary of data type, size and samples used in this thesis.  
 Study Phenotype Cases Controls Data type Ref. 
Paper I       
 WTCCC BD GWAS Bipolar 2938 1868 summary statistics [82] 
 TOP BD GWAS Bipolar 336 198 summary statistics [175] 
 A German BD GWAS Bipolar 1300 682 summary statistics [176] 
       
Paper II       
 TOP genotypes fMRI BOLD 138 108 SNP genotypes [177] 
 TOP fMRI fMRI BOLD 138 108 fMRI voxels [177] 
       
Paper III       
 PGC2 BD cmFDR Bipolar 15,795 22,365 summary statistics - 
 
5.1 THE THEMATIC RESEARCH AREA PSYCHOSIS (TOP) 
The Thematically Organized Psychosis Study (TOP) is a large translational study at 
University of Oslo in collaboration with several psychiatric hospitals in Norway, 
aiming to identify biomedical factors involved in onset and persistence in psychotic 
disorders, with focus on the psychosis disorders bipolar disorder (BD) and 
schizophrenia (SCZ). Inclusion criteria include: between 18 – 65 years, speak a 
Scandinavian language, and fulfil the diagnostic criteria, according to DSM-IV. 
Exclusion criteria were defined as subjects who had suffered major brain trauma or 
any developmental disorders. Diagnosis was set by trained psychiatrists or 
specializing MDs, and reliability of diagnosis and overall agreements for the DSM-IV 
categories has been estimated to be 82%. Included individuals were interviewed to 
register a number of clinical, neurocognitive and psychosocial assessments including 
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onset, relapses, education, alcohol, illegal drug abuse and medication. Several 
neurocognitive and psychosocial functioning were assessed by the following scales 
YMRS [178], PANSS [179], IDS [180], GAF and WASI [181]. The healthy control 
subjects were randomly recruited from the same areas as the patients, and 
interviewed with focus on demographic and clinical information. Inclusion criteria 
were: born in Norway and between 18-60 years. Exclusion criteria were: suffered 
from head injury, mental retardation or neurological disorders or a history of mental 
disorder or close relatives with mental disorders indicated by the Primary Care 
Evaluation of Mental Disorders questionnaire [182]. The TOP project has recruited a 
large number of participants and has currently genotyped, (in the TOP8 data freeze) 
~1577 samples passing quality control of which, 421 are healthy controls, 587 have 
BD (BD I, BD II and bipolar NOS) and 411 have a SCZ diagnosis (schizophrenia, 
schizoaffective and schizophreniform) and 158 have with other diagnosis (including 
major depression and other psychosis).  
5.2 ETHICAL CONSIDERATIONS 
All participants in the overall TOP study gave informed written consent. The TOP 
study has been approved as a bio-bank by the Regional Committee for Medical 
Research Ethics, the Norwegian Data Inspectorate, and the Norwegian Health 
Authority. All genetic and neuroimaging data used in this thesis were de-identified 
before being received, and the identification key have never been used nor been 
accessible. However, there have been some controversy and discussion of the 
traceability of anonymized genome wide data, resulting in strict data sharing and 
storage policies. All genetic and imaging data used in this thesis has been stored on 
password protected and offline external disk drives and will be deleted after the 
completion of this thesis.  
The participants do not necessarily benefit directly from the results presented in this 
thesis, although method development in GWAS in general and in neuroimaging 
genetics may, in the long term, provide better understanding of the biological 
underpinnings of BD.  
5.3 GENOTYPING AND QUALITY CONTROL OF THE TOP SAMPLE 
Part of this thesis included calling the discrete SNP states from raw data and 
performing quality control of the TOP sample. The TOP sample was genotyped on 
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the Affymetrix Genome-Wide Human SNP Array 6.0 platform, measuring 906,600 
SNPs, performed by Expression analysis Inc., Durham, USA and later, at the 
genotyping core facility at the Oslo University Hospital, Norway. Provided with 2235 
raw data files, quality control was performed on two levels, using SNP data and 
using information about the individual samples. First, all raw data were read using 
Affymetrix Power Tools, and the birdseed algorithm version 2 within, was used to call 
the SNP states of the raw data. To avoid batch effects, genotype calling was 
performed in each batch separately (n=33). The called genotypes for all samples 
were then merged and transformed from AB (Affymetrix convention), to actual state 
(ATCG). Then all SNPs were ensured to be located in the same strand (forward 
strand), and genomic physical position (hg18) was provided by Affymetrix annotation 
files. In the next step several sanity checks were performed using PLINK by 
clustering based on pairwise identity by state (IBS). This resulted in the detection of 
sample duplicates (n=391), cryptic duplicates (n=77, same sample, different 
diagnosis) and siblings (n=9 removed, keeping one). Samples with a discrepancy 
between reported and predicted gender were removed (n=24). SNPs significantly 
associated with batch identity were set to missing (p<1x10-8). Then the TOP dataset 
was merged with the reference HapMap III population, and a new IBS clustering was 
performed to identify TOP individuals with a non-European origin, which were 
visually identified by a cluster plot and excluded (n=75). GWAS tend to use different 
threshold for missing data and here a liberal threshold of maximum 5% missing data 
was allowed, further excluding 99 samples. After the initial quality control, 1577 
samples remained, denominated as the “TOP8 QC1” dataset. Further quality control 
of this dataset has been recommended, including minor allele frequency, missing 
rate per SNP and pr. individual and fulfilment of Hardy-Weinberg equilibrium.  
5.4 FUNCTIONAL MRI EXPERIMENT 
Some TOP study individuals participated in several functional MRI (fMRI) 
experiments, including a negative faces paradigm, measuring the hemodynamic 
response in the brain when subjects were given a task to match negatively charged 
faces (sad, angry, frustrated), an experiment designed to measure amygdala activity 
[183]. Data collection, quality control and analysis of this fMRI experiment were 
performed by co-authors of paper II, and are included here for the thesis to be self-
contained. 
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The task was to determine which of two images at the bottom of the screen, was an 
exact match with a target image at the top. The images displayed were either 
negative (angry or afraid) faces (experimental task) or geometric figures 
(sensorimotor control). The individuals solved the tasks with a mean response time 
of 1155 Ms and an accuracy of 98.59%. A block design was used that considered 
consisting of four experimental and five sensorimotor blocks lasting 32.64 seconds 
each. The sessions took 5 minutes and 10 seconds to complete including eight 
dummy disk acquisitions. E-prime software (Psychology Software Tools, Inc.; 
Pittsburgh, PA) controlled the presentations of the stimuli while using VisualSystem 
(NordicNeuroLab, Bergen, Norway). Responses were collected using 
ResponseGrips (NordicNeuroLab Bergen, Norway). 
MRI scans were acquired on a 1.5T scanner (Siemens Magnetom Sonata, Siemens 
Medical Solutions, Erlangen, Germany) supplied with a standard head coil. 152 
volumes (24 axial slices of 4 mm with a 1 mm gap between slices), covering the full 
extent of the brain, were acquired using an EPI BOLD sequence (TR= 2040 Ms, TE= 
50 ms, flip angle=90°, matrix 64 x 64, FOV 192 x 192 mm). The first seven and the 
last volume in each session were treated as dummy disc acquisitions. To improve 
localization, a sagittal T1-weighted 3D Magnetization Prepared Rapid Gradient Echo 
(MPRAGE) volume was acquired (TR=2000 ms, TE=3.9 ms, Flip angle= 7°, 
matrix=128 x 128, FOV 256 x 256 mm). 
Preprocessing and analysis of fMRI data was performed using the SPM2 software. 
All functional volumes were realigned to the first volume, and the anatomical image 
was co-registered to the mean functional image to ensure that they were aligned. 
Images were then spatially normalized, re-sampled at 2x2x2 mm and smoothed, 
using a 6 mm full width-half maximum (FWHM) isotropic kernel. Data was high-pass 
filtered using a cut-off value of 128 s and the AR(1) function as implemented in 
SPM2 was applied. The model was built by convolving boxcar functions for the 
onsets of the two block types (“faces” and “figures”), with a canonical haemodynamic 
response function. Individual contrast images were created by subtracting “figures” 
from “faces”. The contrast images were converted to matrices and submitted for 
further analyses.  
5.5 SUMMARY STATISTICS OF BD GWAS 
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Summary statistics is considered the net result of a GWAS and is a table containing 
statistics for each SNP like chromosome number, physical position, allele frequency, 
odds ratio and p-value for all SNPs. In paper I, collaborators provided summary 
statistics for TOP [175] and a German GWAS of bipolar disorder [176], as well as the 
publically available WTCCC bipolar GWAS [82]. In paper III we obtained the 
significant genes using the cmFDR method of a large and currently unpublished 
GWAS of BD, from collaborators in San Diego, USA. 
5.6 STATISTICAL ANALYSIS 
Briefly, Spearman rank correlation coefficient is used in paper I. principal component 
analysis (PCA), linear regression, Wald test and random permutation test are used in 
paper II, while Fisher’s exact test is used in paper III. Paper I do not access 
significance, while permutation based methods to assess significance and adjusting 
p-values for multiple testing is used in paper II, while in paper III we use Fisher’s 
exact test and false discovery rate [184].  
5.6.1  A NEW TOOL FOR ASSIGNING SNPS TO GENES 
In this study we used the Spearman’s rank correlation coefficient of summary 
statistics (SNPs and p-values) to compare an overall descriptive trend in increased 
concordance between studies when using LD together with physical distance to 
assign SNPs to genes. Spearman rank correlation coefficient is closely related to the 
Pearson’s rank correlation coefficient, but uses ranks instead of raw values. It 
permits the comparison of non-linear variables, and if the ranks within two variables 
are identical, results in a positive Spearman rank correlation coefficient of 1. A 
requirement is that the two variables are monotonic, that is there must be a linear or 
inverse linear relationship between the ranks of the two variables. Calculating 
Spearman’s rank correlation coefficient, without ties, is done with the following 
formula, where di equals the squared difference in rank between each observation of 
the two variables, and n equal the number of observations. In paper I we used R to 
calculate the Spearman’s rank correlation coefficient between the ranked gene lists 
returned from three GWAS studies of BD, before and after LD inclusion. 
    
 ∑  
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5.6.2  APPLYING GENE SET ANALYSIS ON A GWAS USING FMRI ENDOPHENOTYPES 
In this study we used several statistical methods: PCA, linear regression, Wald test 
and random permutation tests. First, we reduce the fMRI data using PCA [185, 186], 
which return eigenvectors for each individuals for several eigenvalues. PCA is a 
mathematical technique that aims to compress or reduce data without loss of (too 
much) information. The method uses the following steps: a) calculate mean within 
the samples b) subtract the mean within the samples c) calculate the correlation 
matrix between the samples. Individual samples are the collection of voxels within 
each individual and we aim to construct new images which represent the majority of 
variance between individuals. d) Eigenvectors and eigenvalues are calculated using 
linear algebra from the square covariance matrix. Then the new “samples” which 
have eigenvalues above the level of noise, visualized in a scree plot [187], are 
identified, and the eigenvectors within are used as quantitative traits in linear 
regression and Wald test to access the significance of SNPs in GWA analysis. 
Detailed examples of PCA on microarray data can be found in [188] and [189].  
First linear regression is used to estimate the regression coefficients of SNPs with 
the quantitative trait (eigenvectors). The regression coefficients are then used in the 
Wald test, which compares the difference between a proposed variable of interests 
(quantitative trait or   ) with the maximum likelihood estimate (regression coefficients 
or  ) divided by the standard error of the likelihood estimate (  , compared to the 
normal distribution.  
       
 
      
 
This yields a p-value for each SNP, which is assigned to genes and gene sets. To 
access the significance of gene sets, we performed random permutation test by 
sample randomization and re-running the regression and Wald test 100,000 times, 
using the number of significant genes within the gene sets, weighted by the 
importance of the eigenvalue as test-statistic, and significance calculated as the 
number of times the null distributions have equal or greater test statistic (   then the 
original test-statistic (  , divided by the number of permutations   . Both the 
numerator and denominator are added by 1 to avoid p = 0.  
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We used R to perform the PCA analysis (“princomp”), PLINK for regression and 
Wald test and to generate the null distributions [190]. Both linear regression and 
Wald test are executed by the “—assoc” function, if PLINK detects a quantitative trait. 
We made a custom R function to weight and access the significance of gene sets. 
5.6.3  EVIDENCE OF OESTROGEN RESPONSIVE GENES IN BIPOLAR DISORDER 
In the last study we use the Fisher’s exact test implemented in “topGO”  to test if any 
GO terms are over-represented among protein interacting- and BD associated genes. 
Fisher’s exact test is frequently used to test differences between categorical data, 
where the data are summarized in 2x2 contingency tables. The test assumes that 
the two groups are independent and mutually exclusive, and yield exact p-values. 
Here we make use of the “weight” function within “topGO” to increase the score of 
children nodes within the GO hierarchy: significance scores of connected nodes (a 
parent and its child) are compared in order to detect the locally most significant 
terms in the GO graph. This is achieved by down-weighting genes in less significant 
neighbours [191].  
5.6.4  RANDOMIZATION TO ACCESS SIGNIFICANCE 
Permutations is a randomization procedure to generate false data, also called null 
distributions, and compare a test statistic from the original data to the test statistic in 
the false data in order to determine statistical significance, originally proposed by 
Fisher in 1935. Ideally all possible permutations (combinations) should be performed, 
but this is often practically impossible for larger data sets, so an approximation is 
needed to perform a fixed but large amount of permutations, proposed by Dwass in 
1957 [192].  
Permutation based methods is a class of non-parametric tests which is 
advantageous when there is reluctance to make assumptions about the distribution 
of the data, have good flexibility, guarantee to control the false positive rate (type I 
errors) [193] and is considered the gold standard for adjustment for multiple testing 
[162, 194]. Permutation based methods have three requirements a) a null hypothesis 
b) a test statistic c) null distribution generated by permuting (with replacement) the 
original data. One critical point is that the null distributions must be permuted in such 
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a way that confounding factors influencing the original data are also present in the 
null distributions. For instance randomizing the individual disease status in a GWAS 
retains several confounding factors which influence the significance of genes like LD, 
gene length and SNP coverage. Randomizing the significance of genes, can create 
skewed null distributions, see figure 1. Given a hypothesis, a test statistic and null 
distributions, a p-value can be easily calculated as the number of times the permuted 
test statistic is equal or exceed the test statistic in the original data divided by the 
number of permutations. For instance if the test statistic in the null data is equal or 
exceed the test statistic in the original data, 10 out of 1000 times, yields a p-value of 
10/1000 = 0.01. Often the numerator and denominator are added by 1, to include the 
original data and to avoid p = 0, important when adjusting for multiple testing [192]. 
Generating all possible permutations yield exact p-values, while permuting a fixed 
number of permutations due to practical considerations is known as Monte Carlo 
permutation tests or random permutation tests, yield approximate p-values [192]. 
Random permutation tests are used in paper II and paper III.  
5.6.5  CORRECTION FOR MULTIPLE TESTING 
When testing a hypothesis, a significance level must be defined and by convention, a 
null hypothesis can be rejected if we can do so with less than 0.05 or 5% probability 
of being wrong. However, modern genetic and molecular biological methods allow 
the measurement of hundreds of thousands of elements, resulting in the testing of an 
equal amount of hypotheses. At a significance level of p<0.05, approximately 5% of 
the elements would be called significant by chance, resulting in thousands of 
significant findings, thus methods to adjusting p-values for multiple testing are 
obligatory in statistical inference of high throughput experiments like GWAS, also 
known as control of the type I error rate [195]. This can be done in several ways, but 
control of the family-wise error rate and false discovery rate are the most common 
methods.  
The most conservative method is to control of the family-wise error rate (FWER), 
defining the level of type I error rate at the probability of at least one type I error. Two 
general branches for control of the FWER exists, single step (same adjustment to all) 
and sequential (rank based). Example of single step control of FWER is the 
Bonferroni adjustment, where type I error rate is simply defined as 0.05 / number of 
tests. Sequential adjustment for control of FWER includes Holm [196]. FWER control 
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of type I error rate guards against any false positive findings. If using permutations it 
is possible to make use of the null distributions in controlling type I errors as 
permutation based FWER control of type I error rate would mean treating each of the 
permutations as original data and count the number of times any hypothesis in all 
permutations is equal or exceed the permuted p-value. This approach is also known 
as the minimum p adjusted p-value [197], and is considered conservative [138] 
(paper II).  
Less conservative than FWER, but arguably more powerful, is control of the false 
discovery rate (FDR) [184]. High throughput experiments are often said by be 
hypothesis free, a substrate for formulating new hypothesis, thus a degree of false 
positive findings may be found acceptable. Control of type I error rate using rank 
based (FDR), is common, especially in gene expression studies, accepting a 
proportion of false discoveries among the total rejected null hypothesis. In paper III 
we adjust the p-values returned from a Fisher’s exact test by the Benjamini-
Hochberg FDR procedure.  
5.7 SOFTWARE 
The studies within this thesis have only used open-source software. 
R / CRAN R (The Comprehensive R Archive Network) is a programming language 
and environment and is used throughout all papers in this thesis. Numerous R 
packages have been used including: IRanges [198] and HDF5 [199], princomp, 
miscTools [200], rgl [201], misc3d [202] and GenomicRanges [203], biomaRt [204], 
stringr [205], iRefR [206] and Cairo [207].  
cran.r-project.org 
PLINK is a command line software, frequently used to perform quality control and 
association analysis in GWAS [190]. Specifically PLINK was used in quality control 
of the TOP genotypes (associated papers), and association analysis in (paper II).  
pngu.mgh.harvard.edu/~purcell/plink 
Affymetrix power tools (APT) APT is a command line collection of functions and 
algorithms tailor made for the analysis of cross platform Affymetrix GeneChip® 
arrays, and was here used to call the discrete genotypes of SNPs from raw data, 
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using the birdseed algorithm (associated papers). 
affymetrix.com/partners_programs/programs/developer/tools/powertools.affx 
5.7.1  SOURCES FOR GENE SET DATA 
As knowledge about genes is accumulating, so do the number of databases, with 
various biomedical scopes. Unifying these databases into single resources is 
convenient and helpful in order to conduct comprehensive analysis of high-
throughput experiments like GWAS. Here, two unifying resources have been used. 
In paper II we use the MSigDB database [138] (version 3.0), a collection of gene sets 
including data from Gene Ontology, KEGG, Biocarta and Reactome. In paper III we 
make use of protein interaction data, unified in the iRefIndex database (version 
6.6.2013), which rely on numerous protein-protein interaction databases including 
BIND, BioGRID, CORUM, DIP, HPRD, InnateDB, IntAct, MatrixDB, MINT, MPact, 
MPIDB, MPPI and OPHID [208]. 
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6 SUMMARY OF RESULTS 
All papers relate to the biological interpretation of GWAS results, applied to BD and 
an endophenotype. Paper I elucidates the effect of adding information from linkage-
disequilibrium between SNPs returned from GWAS of bipolar disorder (BD) when 
assigning SNP to genes, in collaboration with the University of Bergen. In Paper II 
we apply a permutation-based, gene set enrichment method to test the effect of 
SNPs on brain activation patterns during a functional MRI experiment. Finally, in 
paper III we make use of protein-protein interaction data to construct a protein 
interaction network of BD risk proteins and test, if any gene sets are over-
represented among protein interacting genes associated with BD.  
6.1 A NEW TOOL FOR ASSIGNING SNPS TO GENES 
Linkage-disequilibrium-based binning affects the interpretation of GWASs 
Down-stream analysis of GWA results and gene set enrichment methods are 
critically dependant on how SNP are assigned to genes. Typically SNPs within the 
gene boundaries and neighbouring SNPs, defined by an arbitrary physical distance, 
are used to assign SNPs to genes. We argue that using physical distance alone is 
too simplistic as linkage disequilibrium (LD) between SNPs can span over non-
negligible distances.  
As proof of principle we measured the rank correlation of results between three 
GWAS sub-studies of BD, using positional and LD based binning. We reported that, 
by including LD, the mean pairwise rank correlation between studies increases from 
0.03 to 0.06, suggesting that including LD results in an overall increase in agreement 
between studies. We also showed that by including LD, the global SNP coverage 
increases and that genes without any SNPs using positional binning alone, are 
included by using LD.  
We implemented this method in a flexible R package, denominated “LDsnpR”, which 
is computational efficient and uses the pairwise linkage disequilibrium (LD) between 
SNPs pre-calculated from HapMap CEU r27 reference panel, to assign SNP to 
genes based on distance and LD. In addition, we implemented several methods for 
calculating aggregate gene scores.  
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6.2 APPLYING GENE SET ANALYSIS ON A GWAS USING FMRI ENDOPHENOTYPES 
Pathway analysis of genetic markers associated with a functional MRI faces 
paradigm implicate polymorphisms in calcium responsive pathways 
SNP genotypes can be combined with brain imaging data to possibly reveal SNPs 
which influence brain function. However, testing each SNP (~500,000 SNPs) versus 
each voxel (mm3) (~200,000), results in many statistical tests (here 0.1 trillion tests) 
with the following multiple testing issues. Both data types contain a considerable 
degree of correlated measurements and data redundancy. 
We applied principal component analysis on a functional MRI experiment of a 
negative faces task, and used the most important components as quantitative traits 
in a GWAS. SNPs moderately associated (p < 1 x 10-4) with the experiment are used 
in gene set analysis. We permuted the gene set analysis 100,000 times, by sample 
randomization, in order to asses significance and adjust the retuning p-values for 
multiple testing using strict permutation based FWER.  
The most significant gene set was related to post-NMDA receptor activation events, 
although there was no statistical significance after strict adjustment for multiple 
testing. We combined the SNPs within the most significant gene set to localize a 
single with a peak effect in the inferior frontal gyrus, a region involved in risk aversion 
and language production.  
6.3 EVIDENCE OF OESTROGEN RESPONSIVE GENES IN BIPOLAR DISORDER 
Network-based gene set enrichment of genomic regions associated with 
bipolar disorder reveals susceptibility genes responsive to oestrogen stimulus 
Increasing sample size and applying Bayesian statistics in GWAS yield more 
statistically significant SNPs associated with BD. Here, we conduct a protein 
interaction analysis of significant SNPs (n=250) identified by a Bayesian method 
using the summary statistics of PGC GWAS of BD (n cases=15,795). 
Cellular processes are the collective result of protein functions, often organized in 
distinct modules, consisting of groups of physically interacting proteins. Genetic 
disorders are manifestations of perturbing such functional modules. We make use of 
protein-protein interaction data to test if susceptibility genes for BD encode proteins 
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that engage in protein-interactions with other BD susceptibility genes, and if they 
share a biological context represented by Gene Ontology terms.   
We construct a protein-protein interaction network using high confidence protein 
interaction data and identify one biological process, response to oestrogen stimulus, 
as significantly over-represented within protein interactions between BD associated 
genes.
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7 DISCUSSION 
7.1 A NEW TOOL FOR ASSIGNING SNPS TO GENES 
Here we showed that using information of LD between SNPs in a reference panel, 
together with physical distance, improves SNP to gene annotation. Furthermore, in 
the process we developed an R package, “LDsnpR”, for this purpose. More 
specifically, the benefits of using LDsnpR are: a) a framework for assigning SNPs to 
genes using physical position and LD b) to calculate aggregate gene score based on 
annotated SNPs c) to increase the genomic coverage by assigning SNPs to genes 
that do not have any SNPs within its physical boundaries, thus “rescuing” genes. 
This resulted in the annotation and “rescue” of ~7% of all genes. d) To increase 
genomic density, that is, more SNPs are assigned to genes (on average and 
increase from 5.6 to 8.4 SNPs pr. gene). We argue that this gain of information is 
fast, cheap and free and demonstrate the usefulness of this method as the gain in 
the agreement or concordance between GWAS. The three studies of bipolar disorder 
showed an increase in concordance of ~3% of the rank correlation of results, 
compared to only positional based SNP to gene annotation.  
Other studies have also developed methods for SNP to gene assignment using LD. 
This includes a study which describes a Perl script “ProxygeneLD” [144] and another 
study that describes an algorithm, which is currently unavailable “LDspline” [145]. 
The method described in this study, LDsnpR, is faster, more flexible and more user 
friendly than the two other previous methods. LDsnpR also include calculation of 
aggregate gene scores. 
There are some limitations to this study. The main limitation is that we use 
underpowered GWAS of bipolar disorder to demonstrate an increase in concordance 
[118]. The increase in concordance is also quite modest (3%). Another limitation is 
that there are few, but relatively large LD blocks in the human genome, including the 
MHC region of chromosome 6, which by using LDsnpR naively, would result in the 
best scoring SNP within the large LD blocks in this region being assigned to 
numerous genes, resulting in an overall increase in type I errors (FP).  
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The findings in this study have been criticized [209]. The opposing argument is that 
the increase in concordance between studies is due to correlations caused by non-
random LD patterns, and not the same SNP signals. This is also a critique of 
aggregate gene scores of GWA results in general. Although this might be true, the 
systematic interpretation of GWAS requires SNP to gene assignment, but which 
approach is more appropriate is subject to discussion [141, 210, 211]. The current 
consensus in SNP to gene assignment seems to be simple but effective: minimum p-
value of SNPs within or close to genes (+- 20 kbps). This simple “rule” is based on 
findings from eQTL studies, where SNPs influencing gene expression, tend be 
located quite close to the affected gene [142, 212]. The methods GATES [213] and 
VEGAS [214], which aggregate and permutes gene scores using LD patterns, is 
emerging as a gold standard in aggregating SNPs to genes. These algorithms could 
be implemented in future versions of “LDsnpR”.  
LDsnpR is an efficient tool for assigning SNP to genes, with the aforementioned 
benefits. However, SNP imputation [125], computationally inferring the SNP states of 
un-genotyped data is now routinely performed in GWAS, making the increase in 
genomic coverage and density argument provided by “LDsnpR”, obsolete. 
Nonetheless, the main purpose of “LDsnpR” is to provide a framework for SNP to 
gene annotation and to calculate aggregate gene scores, based on physical distance 
and LD, and is still useful even used on imputed SNP data. Another method, GATES, 
takes into account LD patterns when calculating gene based statistics, and yield an 
overall increase in significant findings from GWAS studies [213]. This approach 
could be implemented into LDsnpR to increase its versatility.  
7.2 APPLYING GENE SET ANALYSIS IN A GWAS USING FMRI ENDOPHENOTYPES 
In this study we developed a new method in an attempt to detect SNPs and 
associated gene sets possibly influencing brain function during a particular functional 
MRI (fMRI) experiment. The rationale behind this project was to use methods to 
improve statistical power when combining SNP and brain imaging data. This was 
done on two levels, data reduction of fMRI data and gene set analysis of associated 
SNPs. Data reduction lowers the multiple testing burden and gene set analysis 
increases power to detect moderate, but recurring signals in related genes. We 
applied a computationally intensive method, permuting sample labels and re-running 
References 
 
48 
 
association analysis 100,000 times using five phenotypes, to assess significance by 
permuted p-value and strict adjustment for multiple testing. The main conclusion of 
this project was that we were not able to detect any statistically significant gene sets 
which influenced brain function in this particular fMRI experiment. We were, however, 
able to identify a biological relevant gene set, “post NMDA receptor activation 
events”, which seemed to localize a relevant area in the brain, left inferior frontal 
gyrus, although this is somewhat speculative.  
In this study we used principal component analysis (PCA) of a specific fMRI 
experiment, and treat the returning eigenvectors as endophenotypes in a GWAS. 
Using PCA, it is common practice to evaluate the returning eigenvalues in Scree plot, 
also called The Cattell scree test [187], and keep the eigenvalues above the level of 
noise. In our case the first five components were above the level of noise, capturing 
25% of the variance in the experiment. Thus, the majority of information using this 
approach is lost, an indication of the large individual variability in fMRI experiments, 
which is a major limitation of this study.  
This study was underpowered (n= 246) to detect the small effects of SNPs, but we 
attempt to remedy this using techniques to improve statistical power. The sample 
consisted of healthy controls as well as subjects diagnosed with BD. Although there 
is a large interest in detecting characteristic brain activation signals in BD [215], 
there is no consensus that such signals exist, although several patterns both in 
terms of structural as well as functional areas have been found [216-218]. We 
reasoned that if we were able to detect any significant findings using all subjects, this 
would encourage us to further formulate diagnosis specific hypothesis. As we were 
unable to detect any statistically significant findings using all subjects, we reasoned 
that we would probably not find any significant findings using BD, as this would result 
in a reduction of sample size. There is a large consensus that brain activity 
measured by fMRI shows a large degree of variability between individuals and care 
should be taken when designing, analysing and interpreting results [219]. Several 
sources of variance in an fMRI experiment are well known like anatomy, cranial 
shape, head motion, task paradigm, cognitive strategy, medication, physiological 
noise like heart rate, scanner noise, data analysis method, age, gender, sex and 
genetics [220]. In this study we do not consider nor adjust for any of these sources of 
variability, which may obscure genetic associations. 
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To our knowledge this is the first study performing rigorous gene set analysis using 
global activation patterns from functional MRI experiment as endophenotypes and 
testing these against genome wide SNP markers. Several studies have however 
identified the possible influence of genes using similar approaches including, a 
genome-wide and whole brain association study, but without gene sets analysis, 
using parallel ICA of an oddball fMRI experiment (n=63) [221] and a study using 
candidate genes and structural MRI with subsequent gene set analysis (n=278) [222]. 
However, fMRI studies are characterized by small sample sizes [223], a 
consequence of the labour intensive effort in collecting fMRI data, suggesting that 
most studies, including our own, are underpowered to detect the small effects of 
individual SNPs [47]. The field of imaging genetics are collecting larger and larger 
sample sizes attempting to identify significant SNPs [224, 225], primarily using 
structural MRI (sMRI) as endophenotypes. One of the first GWAS in imaging 
genetics measured the temporal lobe volume by sMRI in 742 Alzheimer’s disease 
patients, found no significant findings (p < 5 x 10-8) [102], while the largest imaging 
genetic study ever performed (2012) (n=7795) used sMRI measurements of 
hippocampal and intracranial volume and found two significant SNPs [224]. Imaging 
genetics is the convergence of advances in genetics and brain imaging, fields which 
by themselves generate large amounts of data [226]. When combined, 
computational and statistical issues rise, complicating the effort in elucidating 
possible common genetic effects on brain structure and function, and new statistical 
methods are under development to handle the amount of correlated tests [227, 228].  
7.3 EVIDENCE OF OESTROGEN RESPONSIVE GENES IN BIPOLAR DISORDER 
In this study we use known protein interactions as a logical filter to test for over-
represented Gene Ontology (GO) terms among protein encoding genes forming 
interactions with other protein encoding genes associated with BD.  
This study is based on the results of on a currently un-published study (Jan 2014) 
using the cmFDR methodology [229, 230] on the most recent PGC GWAS of BD (n 
cases = 15,795 and n controls = 22,365). The identified SNPs (n=250) were 
assigned to 501 protein encoding genes. Between these 501 proteins we identified 
43 protein interactions. While this network may be of qualitative interest by itself, we 
test if these proteins share any biological context using Gene Ontology terms using 
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classical over-representation methods. We found the terms “response to oestrogen 
stimulus” significant after adjustment for multiple hypothesis testing.  
This is not the first time hormonal activity has been associated with BD. A study 
testing for enrichment of GO terms in the WTCCC BD GWAS, reported hormonal 
activity as the best scoring GO term [166]. Fluctuations in oestrogen levels during 
menstrual cycles, after childbirth and menopause have been associated with 
affective episodes and vulnerability to develop depression in females [231, 232]. 
Women with mood disorders have increased risk of experiencing acute episodes 
after childbirth [15928351, 23247604], which may suggests a hormonal influence. 
Although BD is equally prevalent in both genders, rapid cycling BD is more common 
in women. Tamoxifen, a selective oestrogen receptor modulator, primarily used in 
therapy for hormone receptor-positive breast cancer in pre-menopausal women, 
have been shown to be effective in the treatment of mania [233-235], where the 
proposed mechanism is its ability to inhibit protein kinase C. Oestrogen (estradiol) 
has been shown to activate protein kinase C in a variety of cell types including 
neurons [236]. Activation of membrane bound oestrogen receptors in hippocampal 
neurons trigger calcium mediated signalling where neurons expressing membrane 
bound oestrogen receptor,  also co-express the L-class of calcium channels [237, 
238], which includes the prime BD susceptibility gene CANCA1C [39, 239, 240]. This 
might suggest that dysregulation of estradiol activated and calcium mediated 
signalling, and/or activation of PKC by estradiol in BD might be one molecular 
mechanism in the etiology of BD.  It remain unclear if estradiol levels are abnormal in 
individuals suffering from BD or if women BD are more sensitive to fluctuations in 
estradiol levels [241]. The finding in this study is based two layers of knowledge, 
known protein interactions and known gene functions. Thus bias is introduced 
towards well studied proteins, a general issue in gene set enrichment. Further the list 
of BD associated genes is massively reduced from 501 associated protein encoding 
genes from to 43. This is a considerable loss of candidate genes. Nonetheless we 
were able to pinpoint one possible biological process which might contribute to the 
underpinnings of BD etiology.  
7.4 STRENGTHS AND LIMITATIONS 
The main limitation of all studies is statistical power. The first study use 
underpowered GWAS of BD to demonstrate an increase in concordance between 
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studies. The second study is a GWAS of a small sample (n=247) using fMRI as an 
endophenotype and the third study we include nominal significant SNPs. The second 
and third study should be considered as a hypothesis generating study and which 
encourages further validation. However, the main strength of the second and third 
studies is that we do not make biased assumptions of single candidate gene or 
regions of interest. Although these biased assumptions would reduce the multiple 
testing burden, and increase the statistical power, applying such constraints on 
whole-genome or whole-brain data are generally not recommended [242, 243]. 
The field of psychiatric genetics rely on the symptomological classification of mental 
disorders. Defining a quantitative variable in psychiatric genetics would potentially 
increase the statistical power to detect significant findings by adding more 
phenotypes into a single GWAS resulting in an increased sample size, similarly as 
the combined case-control GWAS of five mental disorders, identifying five significant 
findings [244]. A putative study of the same sample using a biomarker or a 
quantitative trait is hampered by the absence of any such biomarkers or missing 
quantitative traits in psychiatric genetics.  
Gene set analysis relies on current biomedical knowledge of genes, and is limited by 
the current understanding of gene functions and how this knowledge is re-phrased 
and annotated in databases. The nature of biocuration makes it lag behind emerging 
experimental knowledge as indicated in by approximately a hundred genes 
annotated with GO term “postsynaptic density” while proteomic studies have 
identified over a thousand proteins localized to the postsynaptic density [245, 246]. 
Gene set analysis used in the second and third studies,  has several other general  
limitations including: overlapping gene sets resulting in issues in multiple testing, low 
resolution in annotation i.e. gene sets terms or gene sets tend to be quite generic 
and the inability to implement or capture the dynamic properties of biological 
processes, in particular cell specific information [247].  
There is no methodological gold standard in gene set analysis and multiple steps 
such as assigning SNPs to genes, different sources of gene sets, database versions 
and different methods to assess statistical significance are sources of variability 
[248]. Although gene set analysis methods have provided invaluable insights in 
numerous studies including GWAS [247, 249] and is routine in interpreting high 
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throughput experiments, the methods has provided somewhat inconclusive results 
when applied to GWAS results in psychiatric genetics [250]. This may be a 
consequence of the current understanding of SNPs and the large gap between 
influential SNPs and reported statistical significant SNPs.  
7.5 CURRENT LARGE SCALE GWAS IN BIPOLAR DISORDER 
The Psychiatric GWAS Consortium, formed in 2010 [116], has conducted the largest 
GWAS of bipolar disorder (BD) to date which includes the TOP sample. The GWAS 
of BD (n cases = 11,977) resulted in four significant findings associated with the 
genes CACNA1C, ODZ4 and two larger regions covering C11orf80 and near DHH. A 
combined GWAS of schizophrenia and bipolar disorder yielded additional significant 
findings in CACNA1C, ANK3 and the ITIH3-ITIH4 region [134]. These overlapping 
findings between schizophrenia (SCZ) and BD have been further refined [244]. Gene 
set enrichment of genes associated with bipolar disorder from the WTCCC study, 
suggested the influence of hormonal processes in BD [166], a result that is similar as 
paper III in this thesis. However, it is difficult to assess the impact of gene set 
enrichment as these findings as it is based on non-significant SNP associations. 
None of these aforementioned GWAS have successfully identified any conclusive 
biological processes or distinct molecular contexts which are perturbed in these 
disorders, although “examination of candidate genes at these loci suggests the 
involvement of neuronal calcium signalling” [251]. Polygenic analysis of the degree 
of liability conferred by SNPs concludes that 25% of the estimated heritability is 
explained by common genetic variation [252], suggesting further increase in sample 
size would yield more significant findings and the application of novel statistics 
methods to increase the number of associated SNPs.  
7.6 CURRENT UNDERSTANDING OF COMPLEX DISEASES 
This thesis is performed in parallel with advances in human genetics and an on-
going debate of the usefulness of GWAS [253-256]. During the five year window 
from the WTCCC study in 2007 [82] to the largest GWAS of date of blood lipids in 
over 200,000 individuals in 2011 [257], several insights have emerged. SNPs are 
highly influential in some complex diseases, in particular, auto immune diseases like 
systemic lupus erythematosis, multiple sclerosis, type I diabetes, and rheumatoid 
arthritis [254]. More specifically GWAS have highlighted biological processes like: 
autophagy in Crohn’s disease, IL-23R pathway in rheumatoid arthritis and factor H in 
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age-related macular degeneration [256]. However, most GWAS of complex diseases 
have not managed to identify the expected number of significant findings indicated 
by the explained heritability of significant findings. Initially this was attributed to the 
small effects of SNPs in general, a need tighten the phenotypic definitions as well to 
increase sample sizes. This inability to identify the bulk of the expected genetic 
susceptibility sparked the missing heritability debate [258, 259], where numerous 
possible factors explaining “the missing heritability” of complex disease have been 
proposed including epistatic effects between SNPs, increased attention towards 
epigenetic mechanisms, rare variants and de-novo events as well a call for more 
sophisticated statistical tools [259-262]. Although statistically significant SNPs only 
explain a small fraction of the estimated heritability, remarkably, a large proportion of 
the estimated heritability is explained by all SNPs, were chromosome length is 
linearly related to explained heritability, suggesting the influence of thousands of 
SNPs in SCZ and BD [250].  
In summary, GWAS have revealed substantial insights in human genetics including a) 
many loci contribute to complex traits b) SNPs are associated to several traits c) 
considering all SNPs (not just the significant ones) explains a large amount of 
additive genetic variation d) SNPs with large effects are almost non- existent [256].  
8 FUTURE PERSPECTIVES 
Genes carry information of how biomolecules interact with the molecular 
environment. Most genes encode proteins, with the evolutionary adaptive purpose to 
interact directly or indirectly with other proteins and biomolecules. The number of 
interactions can sometimes be very high. As such, disease is the organismal 
manifestation of dysfunctional or abnormal interactions between genes in specific 
cellular contexts. Epistasis [263], the non-additive statistical dependence between 
SNPs, or modifier genes of a trait, has been suggested to explain some of the 
observed “phantom” heritability in GWAS [264, 265].  
Many monogenic conditions show incomplete penetrance and variable expressivity 
of traits, where the observable symptoms of the conditions may vary greatly [266]. 
The variable expressivity between individuals is thought to be caused by genetic 
variations of modifier genes within individuals. The influence of modifiers genes in 
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complex diseases may be identified using SNP data. However, the exact 
combinations of modifies genes within individuals is not taken into account in 
conventional GWAS. Hypothetically, individuals suffering from BD may not share a 
universal and common disease mechanism, but possibly several molecular 
dysfunctions may lead to disease, analogously to the many molecular mechanisms 
which may give rise to cell proliferation and cancer. Studies have shown that 
neurological diseases, together with cancer, are genetically heterogeneous and form 
highly interconnected protein networks [254, 267]. For instance the intracellular 
matrix forming the post-synaptic density region, have been shown to be composed of 
over 1,000 proteins [246]. Obviously this structure may dysfunction in numerous 
ways. As such, individuals suffering from a complex disorder like BD may contain 
several, but distinct combinations of modifier genes or codes of epistatic interactions, 
information which is lost during the single marker approach of conventional GWAS, 
which treat each SNP as independent entities across a large number of individuals. 
Statistical testing the dependence between every SNP within every individual is a 
considerable computational task, which may be facilitated by data reduction 
techniques like haplotype phasing, resulting in testing haplotype-haplotype 
interactions within affected individuals, and subsequent gene set analysis of epistatic 
interactions. A recent study using identifying epistatic interactions and subsequent 
gene set enrichment in BD found “enrichment of genes in the cadherin, Wnt and 
axon guidance signalling pathways is suggestive of a developmental origin for BD” 
[268].  
The amount of data generated by modern genetics is enormous, and the brute force 
approach of GWAS including SNP imputation in elucidating the genetics of complex 
human diseases also seems to be its Achilles' heel. The number of hypothesis tests 
is large, even larger in imaging genetics, and as statistical methods to adjust for 
multiple hypothesis testing require independence, results in a substantial amount of 
type II errors. Many consider permutation based methods as the gold standard in 
statistical inference. However, the reluctance to share raw GWAS data together with 
computational practicalities, makes permutation based methods and sample 
randomization rare in GWAS.  
GWAS of BD disorders have revealed the influence of ten thousand SNPs [244]. 
However, the inability to identify converging and distinct disease mechanisms, 
   References
55 
 
including through gene set analysis, seems to be caused by the absolutely tiny 
effects of a very large number of SNPs related to genes which participate in several 
biological processes, a scenario the current gene set analysis methods are not 
developed to take into account. In hindsight, it may not be very surprising that SNPs 
with large disease causing effects do not exit, as evolutionary forces would weed out 
such alternations before it became distributed within a population.  
Even though all SNPs substantiate a considerable degree of the estimated 
heritability in BD, the majority of the estimated heritability remains unaccounted for 
and may reflect the importance of other mechanisms proposed during the missing 
heritability discussion including epistatic interactions between genetic variants, gene 
and environment interactions, improve definitions of phenotypes, elucidate effects of 
sex chromosomes and increase in focus on other genetic alterations like rare 
variants, de-novo mutation and epigenetics [259]. Paternal age have shown strong 
associations with the disorders autism and schizophrenia [269], and given the 
overlapping susceptibility demonstrated by GWAS and shared clinical symptomology 
between SCZ and BD, paternal age may also be associated with BD. A very recent 
study showed an increased hazard ratio between offspring of young and old fathers, 
where children of older fathers have an increased hazard ratio of 24 for developing 
bipolar disorders [270].  This may emphasize the importance of de novo mutations in 
forming susceptibility to severe mental disorders.  
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9 CONCLUSIONS  
In this work several approaches have been used in an attempt to better appreciate 
GWAS results in general and BD in particular. The first study attempts to improve 
methods to facilitate the non-trivial task of assigning SNP to genes and has broad 
applications, although the specific gain in BD research is limited. In the second study 
we attempt to identify biological related genes which are associated with neural 
activation patterns, and represent a novel analytical method in brain imaging 
genetics in general. However, as we were unable to detect any significant findings, 
and we decided to not test BD specific hypothesis further, as this would result in 
reduction of sample size and further loss of statistical power. In the last study we 
make use of protein interactions between BD risk genes, in an attempt to identity any 
over-represented biological process among protein interactions between BD risk 
genes, resulting in a significant over-representation of oestrogen responsive genes. 
The last study raises a hypothesis which is clinically relevant to mood disorders and 
further experimental work could relatively easily determine oestrogen levels during 
mood cycles in individuals with BD as well as controls, which is currently not well 
described in the scientific literature. However, six genes are causing the enrichment 
of oestrogen, and polygenic analysis suggests the influence of thousands of SNPs, 
and as such, the oestrogen hypothesis may represent one of many processes 
involved in forming susceptibility to BD.  
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